Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 14:S0969-2126(25)00264-3.
doi: 10.1016/j.str.2025.07.015. Online ahead of print.

The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody

Affiliations

The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody

Reda Rawi et al. Structure. .

Abstract

The N terminus of the H3 subtype of influenza virus hemagglutinin is ∼10 residues longer than the N termini of most other hemagglutinins. As conserved, exposed, and linear regions may be good vaccine targets, we investigated the vaccine utility of the extended H3-N terminus. First, we identified antibody 5E10, for which structure and binding analyses revealed recognition of the H3-N terminus. Second, we immunized mice with immunogens incorporating the H3-N terminus, boosted with hemagglutinin trimer, and isolated antibodies from immunogen-elicited B cells that bound both H3-N terminus and hemagglutinin trimer. However, hemagglutinin-complex structures of two such antibodies, 3864-6 and 3864-10, that neutralized H3-influenza strains, revealed only peripheral recognition of the hemagglutinin N terminus. Collectively, these results reveal the N terminus of H3 hemagglutinin to be a suboptimal vaccine target and suggest that-in addition to being conserved, flexible, and accessible-other factors influence the elicitation of potent broadly neutralizing responses.

Keywords: cryo-EM; immune focusing; influenza H3 N terminus; peptide immunization; prime-boost; structure-based vaccine design.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

References

    1. Ferguson NM, Galvani AP, and Bush RM (2003). Ecological and immunological determinants of influenza evolution. Nature 422, 428–433. 10.1038/nature01509. - DOI - PubMed
    1. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, and Holmes EC (2008). The genomic and epidemiological dynamics of human influenza A virus. Nature 453, 615–619. 10.1038/nature06945. - DOI - PMC - PubMed
    1. Bouvier NM, and Palese P (2008). The biology of influenza viruses. Vaccine 26 Suppl 4, D49–53. 10.1016/j.vaccine.2008.07.039. - DOI - PMC - PubMed
    1. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, and Detours V (2001). Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 58, 19–42. 10.1093/bmb/58.1.19. - DOI - PubMed
    1. Mkhize NN, Yssel AEJ, Kaldine H, van Dorsten RT, Woodward Davis AS, Beaume N, Matten D, Lambson B, Modise T, Kgagudi P, et al. (2023). Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials. PLoS Pathog 19, e1011469. 10.1371/journal.ppat.1011469. - DOI - PMC - PubMed

LinkOut - more resources